Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Containing Coronavirus Disease 19 (COVID-19) Trial (ConCorD-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04552379
Recruitment Status : Completed
First Posted : September 17, 2020
Last Update Posted : September 10, 2021
Sponsor:
Collaborator:
Telethon Kids Institute
Information provided by (Responsible Party):
Pontificia Universidad Catolica de Chile

Brief Summary:

In recent months severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has emerged as a novel human pathogen and, susceptibility amongst humans is presumed to be universal. Prevention measures of COVID-19 have included distancing, quarantines, use of facemasks in public places, and hand hygiene measures. Mandatory quarantines have also been applied on index cases and their contacts, as well as an active search for asymptomatic patients.

Current strategies to reduce the spread of SARS-CoV-2 do not include measures that could prevent transmission prior to the onset of symptoms. Subjects infected with SARS-CoV-2 have been known to shed virus and be contagious for up to 5 days prior to developing symptoms ('pre-symptomatic transmission'). In fact, nearly 60% of all infected subjects can shed virus pre-symptomatically. Pre- or even asymptomatic shedding occurs across all age groups, contributing to the rapidly expanding pandemic.

Post-exposure prophylaxis (PEP) using type 1 interferon (IFN) can potentially eliminate the spread of SARS-CoV-2. IFN could reduce the period of viral shedding by ~1 week. Since pre-symptomatic shedding of virus can start up to 5 days prior to symptom onset, our approach of a PEP intervention to all contacts recently exposed to a case could possibly entirely interrupt the spread of the virus, and with that, the pandemic. The current study focuses on prevention of the disease in addition to its treatment. Thus, the key distinction between these other trials and this study is that this study focuses on containing coronavirus (i.e. cause) in the community, rather than simply its treatment (i.e. consequence) in the individual.

Viral spread could be eliminated through interventions effective at abolishing viral transmission. However, such post-exposure prophylaxis interventions, that is initiation of antiviral therapy in pre-infectious contacts to reduce or even eliminate such spread, must be safe since they are given to asymptomatic and possibly uninfected subjects. In none of the previous clinical trials of IFN therapy for SARS-CoV-2 have serious adverse events been recorded. Furthermore, the IFN chosen for this study (pegylated IFN 1b) has been extensively studied in clinical trials, and has been in clinical use for years for multiple sclerosis. Pegylated IFN formulations allow for weekly injections while maintaining serum levels and limiting dose-dependent side effects. Together these data support a sound safety profile for the planned intervention.

The aim of this study is to ascertain whether IFN administered to index cases and household contacts of an index case, starting immediately following confirmed exposure (index case confirmed positive for SARS-CoV-2), will reduce duration of SARS-CoV-2 detectable by PCR in the index cases, and incidence of SARS-CoV-2 detectable by PCR in household contacts.


Condition or disease Intervention/treatment Phase
SARS-CoV Infection Interferon Covid19 Biological: Peginterferon beta-1a Phase 3

Detailed Description:
Participants with COVID-19 will be identified from lists of patients with positive SARS-CoV-2 PCR that is obtained daily from clinical laboratories, at COVID-19 outpatient and hospital clinics, or the Emergency Rooms in Chile. After telephonically pre-screening eligibility of the index case and his/her household, and participants providing informed consent, households will be randomized 1:1 to three doses of IFN beta 1a or standard of care. Only the index case and treatment-eligible household members will receive IFN if their household is assigned to treatment arm. Other non-eligible household participants (e.g. children) will be monitored by serial SARS-CoV-2 saliva PCR and diary cards, and at day 29 all participants will be evaluated for SARS-CoV-2 antibodies in blood.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1173 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

A prospective, cluster randomised trial of interferon versus standard of care. Index cases will be identified from databases of positive COVID-19 PCR patients from the virology lab,('Fever') clinics, outpatient clinics and hospital emergency room visits for possible COVID-19. Household contacts will be identified via the index cases and will be approached with the consent of the index case.

Randomisation: Households will be randomised to receive IFN or standard of care (as recommended by the Public Health Department).

Trial population: Index cases positively infected with SARS-CoV-2 and their exposed household contacts. Index cases will be recruited from databases of individuals with confirmed COVID-19 identified from COVID-19 ('Fever') clinics and emergency room visits in Santiago, Chile.

Eligibility criteria: Households will be randomised only if cases and at least one treatment-eligible household contact meets all the inclusion criteria and none of the exclusion criteria.

Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Cluster Randomised Trial of Interferon Versus Standard of Care in the Reduction of Transmission of SARS-Cov-2. The Containing Coronavirus Disease 19 Trial (ConCorD-19)
Actual Study Start Date : December 1, 2020
Actual Primary Completion Date : May 31, 2021
Actual Study Completion Date : June 30, 2021


Arm Intervention/treatment
Active Comparator: Interferon
Peginterferon beta-1alfa will be made available from Biogen Inc. Switzerland. 125 micrograms of pegylated IFNß1alfa (PLEGRIDY, Biogen) administered on Study Days 1, 6 and 11 (i.e. for a total of 3 doses) via subcutaneous injection.
Biological: Peginterferon beta-1a

Administration of trial drug: PLEGRIDY is given by an injection under the skin (subcutaneous injection). It will be administered to participants in accordance with product insert instructions by appropriately trained trial staff for whom administration of subcutaneous injections is within their normal scope of practice (e.g. RN or MD). They will wait for 20 mins after the last individual receives the interferon before leaving a residence. Administering staff will be supplied with appropriate PPE, trained in the use of this equipment and protocols for infection control, and will always attend in pairs.

PLEGRIDY will be administered in the home of the participants. Due to the heat-labile nature of the trial product (storage required at ~4oC) a verified English Spanish version of the product label will be printed by a GMP certified company and applied to the product and patient band just at the time of use.

Other Name: Plegridy

No Intervention: Standard of Care
Standard of Care; following national guidelines regarding self-isolation and infection prevention



Primary Outcome Measures :
  1. The proportion of index cases shedding SARS-CoV-2, at Day 11, in the active arm compared to the standard of care arm. [ Time Frame: Day 11 ]
  2. The proportion of household contacts shedding SARS-CoV-2, at Day 11, in the active arm compared to the standard of care arm. [ Time Frame: Day 11 ]

Secondary Outcome Measures :
  1. Duration (in days) of SARS-CoV-2 by PCR of samples taken on study days 1, 6, 11, 16, 21, and 29. [ Time Frame: Days 1,6,11, 21 and 29 ]
  2. Number of household contacts of participants in the IFN arm with positive upper airway PCR compared to that in the standard of care arm at day 1 & 11, and seroconversion (Ig) over the study period, up to day 29. [ Time Frame: Days 1,11 and 29 ]
  3. The proportion of infected cases in the active arm that are hospitalised or die due to COVID-19, as compared to the proportion in the standard of care arm. [ Time Frame: Days 1 to 29 ]
  4. Incidence and severity of reported adverse events in the interferon arm compared to the standard of care arm. [ Time Frame: Days 1 to 29 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 79 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Index Cases:

    • Provided a signed and dated informed consent form
    • Aged 18 to <80 years of age
    • Confirmed SARS-CoV-2 diagnosis by PCR within 72 hours of first treatment dose
    • The first known diagnosis in the household
    • Not currently enrolled in a clinical trial and agree to not take any other investigational treatments over the next 28 days
    • Must plan to remain resident in the household during the study
    • Lives in household with at least one other 'treatment-eligible household contact'
  2. Treatment-eligible Household Contacts:

    • Provided a signed and dated informed consent form
    • Aged 18 to <80 years of age,
    • Not currently enrolled in a clinical trial and agree to not take any other investigational treatments over the next 28 days
    • Must plan to remain resident in the household during the study
    • No history of previously confirmed SARS-CoV-2 diagnosis
  3. Treatment-ineligible Household Contacts:

    • Provided a signed and dated informed consent form, parental informed consent, and assent if applicable
    • Under 18 years OR ≥ 80 years of age OR aged 18 to <80 years with any contraindication for IFN treatment listed in 'exclusion criteria'
    • Not currently enrolled in a clinical trial and agree to not take any other investigational treatments over the next 28 days
    • Must plan to remain resident in the household during the study
    • No history of previously confirmed SARS-CoV-2 diagnosis

Exclusion Criteria:

  1. Index Cases and Treatment-eligible Household contacts:

    • Inability to take medications orally or injected
    • Known sensitivity/allergy to interferons or use of interferons for another indication
    • Known adverse drug-drug interactions with any study drugs
    • Malignancy
    • Known clinical immune deficiency
    • Pregnancy or unwillingness, of female participants of childbearing potential to use recognised methods of birth control/contraception during the trial period,
    • Retinopathy,
    • Known grade 4 or 5 chronic kidney or liver disease,
    • Known arrhythmias,
    • Known autoimmune diseases or chronic inflammatory disease,
    • Chronic liver disease,
    • Hospitalisation for depression in the last 3 months,
    • Current suicidal ideation,
    • Previous therapeutic use of IFN
  2. All subjects:

    • Declined participation,
    • The index case has been in complete self-quarantine from other household members during the 48 hours prior to diagnosis of SARS-CoV-2 infection.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04552379


Locations
Layout table for location information
Chile
Pontificia Universidad Católica de Chile
Santiago, Chile
Sponsors and Collaborators
Pontificia Universidad Catolica de Chile
Telethon Kids Institute
Investigators
Layout table for investigator information
Principal Investigator: Jose A Castro-Rodriguez, MD,PhD Pontificia Universidad Catolica de Chile, Santiago, Chile
Principal Investigator: Stephen Stick, MD,PhD Telethon Kids Institute, University of Western Australia, Perth, Australia
Study Director: Arturo Borzutzky, MD Pontificia Universidad Catolica de Chile, Santiago, Chile
Study Chair: Carolina Iturriaga, NP Pontificia Universidad Catolica de Chile, Santiago, Chile
Study Chair: Tobias Kollmann, MD,PhD Telethon Kids Institute, University of Western Australia, Perth, Australia
Study Chair: Eleanor N Fish, PhD Department of Immunology, University of Toronto, Canada
Study Chair: Cecilia Perret, MD Pontificia Universidad Catolica de Chile, Santiago, Chile
Study Chair: Diego Garcia-Huidobro, MD,PhD Pontificia Universidad Catolica de Chile, Santiago, Chile
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Pontificia Universidad Catolica de Chile
ClinicalTrials.gov Identifier: NCT04552379    
Other Study ID Numbers: 200703013
First Posted: September 17, 2020    Key Record Dates
Last Update Posted: September 10, 2021
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: We are evaluating the best way to share the information.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Time Frame: We are evaluating the best time to share the information.
Access Criteria: We are evaluating the best way to share the information.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Severe Acute Respiratory Syndrome
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases